Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.
Researchers evaluated the efficacy and safety of avacopan for the treatment of ANCA-associated vasculitis.
Study leads Shilpa Venkatachalam, MD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.
Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.
Investigators characterized the effects and markers of response of omalizumab in normocomplementemic urticarial vasculitis.
Researchers in the PEXIVAS trial evaluated and challenged the effect of plasma exchange and glucocorticoid use in ANCA-associated vasculitis.
An expert panel of clinicians developed guidelines for the use of rituximab in the maintenance of remission for adult ANCA-associated vasculitis.
A recent case report examined the adverse effects of alemtuzumab in a patient with relapsing remitting multiple sclerosis.
Researchers compared the efficacy of plasma exchange vs no plasma exchange, in terms of end-stage kidney disease or death, in patients with severe ANCA-associated vasculitis.
Researchers reported on the outcomes of treatment-refractory, corticosteroid-dependent patients with eosinophilic granulomatosis with polyangiitis with severe asthma.